Dopamine and Citicoline-Co-Loaded Solid Lipid Nanoparticles as Multifunctional Nanomedicines for Parkinson’s Disease Treatment by Intranasal Administration
Authors:
- Stefano CastellaniStefano Castellani
- Giorgia Natalia IaconisiGIGiorgia Natalia Iaconisi
- Francesca TripaldiFTFrancesca Tripaldi
- Vito PorcelliVPVito Porcelli
- Adriana TrapaniATAdriana Trapani
- Eugenia MessinaEMEugenia Messina
- Lorenzo GuerraLGLorenzo Guerra
- Cinzia Di FrancoCFCinzia Di Franco
- Giuseppe MaruccioGiuseppe Maruccio
- Anna Grazia MonteduroAnna Grazia Monteduro
- Filomena CorboFilomena Corbo
- Sante Di GioiaSante Di Gioia
Open Access
- 7 August 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (8) , 1048
Abstract
This work aimed to evaluate the potential of the nanosystems constituted by dopamine (DA) and the antioxidant Citicoline (CIT) co-loaded in solid lipid nanoparticles (SLNs) for intranasal administration in the treatment of Parkinson disease (PD). Such nanosystems, denoted as DA-CIT-SLNs, were designed according to the concept of multifunctional nanomedicine where multiple biological roles are combined into a single nanocarrier and prepared by the melt emulsification method employing the self-emulsifying Gelucire® 50/13 as lipid matrix. The resulting DA-CIT-SLNs were characterized regarding particle size, surface charge, encapsulation efficiency, morphology, and physical stability. Differential scanning calorimetry, FT-IR, and X ray diffraction studies were carried out to gain information on solid-state features, and in vitro release tests in simulated nasal fluid (SNF) were performed. Monitoring the particle size at two temperatures (4 °C and 37 °C), the size enlargement observed over the time at 37 °C was lower than that observed at 4 °C, even though at higher temperature, color changes occurred, indicative of possible neurotransmitter decomposition. Solid-state studies indicated a reduction in the crystallinity when DA and CIT are co-encapsulated in DA-CIT-SLNs. Interestingly, in vitro release studies in SNF indicated a sustained release of DA. Furthermore, DA-CIT SLNs displayed high cytocompatibility with both human nasal RPMI 2650 and neuronal SH-SY5Y cells. Furthermore, OxyBlot assay demonstrated considerable potential to assess the protective effect of antioxidant agents against oxidative cellular damage. Thus, such protective effect was shown by DA-CIT-SLNs, which constitute a promising formulation for PD application.Keywords
This publication has 61 references indexed in Scilit:
- Research progress on intranasal treatment for Parkinson's diseaseNeuroprotection, 2024
- Multifunctional nanomedicine strategies to manage brain diseasesDrug Delivery and Translational Research, 2022
- Epigallocatechin-3-gallate inhibits the growth of three-dimensional in vitro models of neuroblastoma cell SH-SY5YMolecular and Cellular Biochemistry, 2021
- Intranasal drug delivery: opportunities and toxicologic challenges during drug developmentDrug Delivery and Translational Research, 2021
- Development and validation of stability indicating chromatographic methods for simultaneous determination of citicoline and piracetamJournal of Separation Science, 2020
- Dopamine Cytotoxicity on SH-SY5Y Cells: Involvement of α-Synuclein and Relevance in the Neurodegeneration of Sporadic Parkinson’s DiseaseNeurotoxicity Research, 2019
- The Characterization of the Human Nasal Epithelial Cell Line RPMI 2650 Under Different Culture Conditions and Their Optimization for an Appropriate in vitro Nasal ModelPharmaceutical Research, 2014
- Citicoline Protects Brain Against Closed Head Injury in Rats Through Suppressing Oxidative Stress and Calpain Over-ActivationNeurochemical Research, 2014
- Development and analytical characterization of vitamin(s)-loaded chitosan nanoparticles for potential food packaging applicationsJournal of Nanoparticle Research, 2013
- Frog intestinal sac: A new in vitro method for the assessment of intestinal permeability**Part of this article was presented at the European Conference on Drug Delivery and Pharmaceutical Technology, Sevilla, Spain, May 10–12, 2004.Journal of Pharmaceutical Sciences, 2004